Apellis Pharmaceuticals Acquired by Biogen; Shares to Delist

summarizeSummary

Apellis Pharmaceuticals has been acquired by Biogen, becoming a private subsidiary, with its stock set for delisting from Nasdaq.

check_boxKey Events

• Merger Completed

  Biogen successfully completed its tender offer, acquiring approximately 82.4% of outstanding shares, and subsequently merged with Apellis Pharmaceuticals. Apellis is now a wholly-owned subsidiary of Biogen.

• Shares Delisted

  Apellis common stock will be delisted from Nasdaq, with trading suspended effective May 13, 2026, and the company intends to terminate its SEC reporting obligations.

• CVR Agreement Finalized

  A Contingent Value Rights (CVR) Agreement was entered, outlining potential future payments of up to $4.00 per CVR based on SYFOVRE® and related product net sales milestones of $1.5 billion and $2.0 billion in specified calendar years.

• Convertible Notes Treatment Defined

  The merger triggered a 'Fundamental Change' and 'Make-Whole Fundamental Change' for the 3.500% Convertible Senior Notes due 2026, granting holders rights to repurchase or convert notes into cash and CVRs.

auto_awesomeAnalysis

This 8-K confirms the successful completion of Biogen's acquisition of Apellis Pharmaceuticals for approximately $5.3 billion in cash, plus contingent value rights (CVRs). The company is now a wholly-owned subsidiary of Biogen, leading to the delisting of its common stock from Nasdaq and the termination of its SEC reporting obligations. This marks the final stage of a major M&A event, fundamentally changing the company's status and the investment thesis for its former shareholders. The stock is trading near its 52-week high, reflecting the market's anticipation of this finalization.